Pembrolizumab plus ultrasound bubbles for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial combines the immunotherapy drug pembrolizumab (Keytruda) with a special ultrasound technique that uses tiny bubbles to make the treatment work better. It is for people with HPV-negative head and neck cancer that has come back or spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have HPV-negative head and neck cancer that has returned or spread.
- Your tumor must be in a spot that can be reached with an ultrasound probe and a biopsy needle.
- You must be at least 18 years old and in generally good health (able to do daily activities).
- You cannot have had immunotherapy with drugs like Keytruda or Opdivo before.
- You must not have serious heart problems, active infections, or other uncontrolled illnesses.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests pembrolizumab (an immunotherapy) plus chemotherapy to treat head and neck cancer that has come back or spread. You might be eligible if standard local treatments won’t be curative and your tumor can be measured on scans.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus a targeted therapy (cetuximab) for people with advanced head and neck cancer that has gotten worse after treatment with pembrolizumab (with or without initial chemotherapy). The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
This trial tests a new way to give chemotherapy (pulsed doses) together with pembrolizumab (an immunotherapy) for people with head and neck cancer that has come back or spread and cannot be cured with local treatments. The goal is to see if this combination works better than standard approaches.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial studies whether pembrolizumab plus chemotherapy (platinum and gemcitabine) can control recurrent or metastatic head and neck squamous cell carcinoma that can’t be cured with local treatments. It may help shrink tumors and slow disease growth in people who haven’t had cancer medicines for this stage before.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.